Immunological features of alpha-synuclein in Parkinson's disease.
about
The role of oxidative stress in Parkinson's diseasePropagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.The nitric oxide-cyclic GMP pathway regulates FoxO and alters dopaminergic neuron survival in DrosophilaGDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body DementiaMechanisms underlying inflammation in neurodegenerationGlial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants.Hypochlorite-induced structural modifications enhance the chaperone activity of human α2-macroglobulin.Synthesis and biological evaluation of substituted N-[3-(1H-pyrrol-1-yl)methyl]-1,2,5,6-tetrahydropyridin-1-yl]benzamide/benzene sulfonamides as anti-inflammatory agentsCSF from Parkinson disease patients differentially affects cultured microglia and astrocytes.Development of a grape seed polyphenolic extract with anti-oligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathiesTriggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies.Prenatal LPS increases inflammation in the substantia nigra of Gdnf heterozygous miceAltered serum IgG levels to α-synuclein in dementia with Lewy bodies and Alzheimer's disease.Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-SynucleinopathyEnvironmental neurotoxic pesticide dieldrin activates a non receptor tyrosine kinase to promote PKCδ-mediated dopaminergic apoptosis in a dopaminergic neuronal cell model.Proteolytic cleavage of extracellular α-synuclein by plasmin: implications for Parkinson disease.Automated Ex Situ Assays of Amyloid Formation on a Microfluidic PlatformAmyloidogenic α-synuclein seeds do not invariably induce rapid, widespread pathology in mice.Amyloid formation by the pro-inflammatory S100A8/A9 proteins in the ageing prostate.Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy.Analysis of protein levels of 24 cytokines in scrapie agent-infected brain and glial cell cultures from mice differing in prion protein expression levelsInduction of CNS α-synuclein pathology by fibrillar and non-amyloidogenic recombinant α-synucleinNeurodegenerative disorders and nanoformulated drug development.Polyphenolic compounds for treating neurodegenerative disorders involving protein misfolding.Inflammation in the early stages of neurodegenerative pathologySubventricular zone under the neuroinflammatory stress and Parkinson's disease.Fractalkine Mediates Communication between Pathogenic Proteins and Microglia: Implications of Anti-Inflammatory Treatments in Different Stages of Neurodegenerative Diseases.The prion hypothesis of Parkinson's disease.The function of NOD-like receptors in central nervous system diseases.Type-1 interferons contribute to the neuroinflammatory response and disease progression of the MPTP mouse model of Parkinson's disease.Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.Late stages of hematopoiesis and B cell lymphopoiesis are regulated by α-synuclein, a key player in Parkinson's disease.Anti-inflammatory effects of pioglitazone on iron-induced oxidative injury in the nigrostriatal dopaminergic system.Osteopontin polymorphic susceptibility factor for Parkinson's disease among patients with Gaucher disease.Role of Inflammasomes in Neuroimmune and Neurodegenerative Diseases: A Systematic Review.Molecular mechanisms of omega-3 fatty acids in the migraine headache.Biochemical and immunological aspects of protein aggregation in neurodegenerative diseases
P2860
Q24307946-CC617E34-8C3F-4484-B17A-964C824DDA85Q27322513-6CD76C4C-D94D-4278-871E-D77AA03608D4Q28481326-F231B455-DC23-4A7A-BB6C-A8843C398FFCQ28550541-3B6BF7B9-DB4F-4046-AF9F-1FEC5E40AE56Q29617977-9B6A6E4F-B211-41DC-858B-C8E400CBDD66Q30991616-B1AC2C5D-1EE3-496B-B85D-7CC51CBCDFFCQ33665370-FE660C72-FECD-40B5-AA9C-CBACB7783A4BQ33703744-DCE7BED9-6789-46AD-AFE4-589E1DF51A90Q33757872-F7775DA1-C5A0-4BCD-99EC-BF53AEFD70F6Q34154643-BE3BA6A1-2444-4C25-B291-197021968FA8Q34576478-3B1200DE-6304-4E09-925D-7A83BD0D970AQ34587666-5A1D8ECF-EAA3-4935-91AF-E0A946D39F8FQ34760606-A9234B9D-055B-4FA9-AE05-EE0E6E32391BQ35019131-CE8CB74C-B060-4968-BBAF-987B75AE8FC0Q35893513-EA47ECC2-E571-414F-97D8-A2D32BAEA82EQ36127050-456D95B7-E32F-48D1-A388-029FFC1F286FQ36552590-90698FD0-7D52-4D7A-B6BB-396CF6E58521Q36907399-58E0D13A-8B06-4805-BB6F-46AAF648CEF4Q37182479-808519DF-7501-4D00-8D25-70C034037298Q37221349-58CBB8BE-E02C-44D2-9111-FD0345B86C0FQ37410864-A7CD0741-4A03-47FB-A8AF-DBB0E876438EQ37484884-0F30FB64-6271-4DF4-BF5F-C8E419F4CFC4Q37538771-94082D51-6749-4CE4-8FE3-A6C27715CF07Q37775038-151315EC-5E4C-4F6F-A74A-AA9C984A35ECQ37912590-766E308D-933A-4DA0-B1FF-E3A8D5FB4AB3Q37970601-9E445DA4-99B1-4894-9D4D-BCCCC20EC5C5Q38037524-22FAC1FC-BE3F-4B59-BEB3-03ADD555835EQ38418624-B6EB23DE-CDD1-4D9A-BD89-41DDB850532EQ39061008-1A7625FE-AFE7-4665-A72C-1B02D9B3442AQ39609930-39FCA6D0-1CE7-4DC7-BE69-3CA2433B3428Q40768273-E4EF57E2-59AF-45C6-9A85-051A73A7C3AEQ40834797-3306E081-E4F9-467B-A2C9-23B411CC502EQ42971824-1208B159-37D7-4F1C-9994-C3D8F7E43335Q43792274-C30D424B-F64E-4763-A159-A3446BBFD2B4Q55043675-57B82BE4-CB5B-4077-A1AA-CC207E7B63CEQ55423174-22D43989-5320-4953-BF77-3AF6FC1266C1Q57405353-DE1FE196-531A-49E3-B5AE-96B19F56E976
P2860
Immunological features of alpha-synuclein in Parkinson's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunological features of alpha-synuclein in Parkinson's disease.
@en
Immunological features of alpha-synuclein in Parkinson's disease.
@nl
type
label
Immunological features of alpha-synuclein in Parkinson's disease.
@en
Immunological features of alpha-synuclein in Parkinson's disease.
@nl
altLabel
Immunological features of α-synuclein in Parkinson's disease
@en
prefLabel
Immunological features of alpha-synuclein in Parkinson's disease.
@en
Immunological features of alpha-synuclein in Parkinson's disease.
@nl
P2860
P921
P1476
Immunological features of alpha-synuclein in Parkinson's disease.
@en
P2093
John Christodoulou
P2860
P304
P356
10.1111/J.1582-4934.2008.00450.X
P577
2008-07-30T00:00:00Z
2008-10-01T00:00:00Z